Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply

Affiliations

Comment

Ronny Alcalai et al. Eur Heart J Cardiovasc Pharmacother. 2022.

. 2022 Jan 5;8(1):E3.

doi: 10.1093/ehjcvp/pvab074.

¹ Cardiac Care Unit, Mt. Scopus Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem 9124001, Israel.

No abstract available

Comment on

Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial‡.
Alcalai R, Butnaru A, Moravsky G, Yagel O, Rashad R, Ibrahimli M, Planer D, Amir O, Elbaz-Greener G, Leibowitz D. Alcalai R, et al. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):660-667. doi: 10.1093/ehjcvp/pvab057. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34279598 Clinical Trial.
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction.
Sulzgruber P. Sulzgruber P. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):E1-E2. doi: 10.1093/ehjcvp/pvab072. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34543406 No abstract available.